Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.

# Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial   The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.  **Read the full article:** [CNBC](https://www.cnbc.com/2025/12/11/eli-lillys-weight-loss-drug-retatrutide-clears-first-late-stage-study.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*